

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)



(10) International Publication Number
WO 2021/151119 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) C12N 5/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/070073

(22) International Filing Date:

23 January 2021 (23.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/964,947 23 January 2020 (23.01.2020) US

(71) Applicants: **EXUMA BIOTECH CORP.** [US/US]; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). **BIOATLA, LLC** [US/US]; 11085 Torreyana Road, Suite 100, San Diego, California 92121 (US).

(72) Inventors: **FROST, Gregory Ian**; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). **ONUFFER, James Joseph**; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). **KUNDU, Anirban**; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). **SHORT, Jay M**; 12985 Via Esperia, Del Mar, California 92014 (US). **FREY, Gerhard**; 13768 Via Cima Bella, San Diego, California 92129 (US). **CHANG, Hwai Wen**; 1318 Shadow Hills Drive, San Marcos, California 92069 (US).

(74) Agent: **VACCHIANO, Emanuel**; 8110 Woodside Lane, Burr Ridge, Illinois 60527 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: CHIMERIC ANTIGEN RECEPTORS TO HER2 AND METHODS OF USE THEREOF




FIG. 11

(57) Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.

[Continued on next page]

WO 2021/151119 A1

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))